Charles Schwab’s Royalty Pharma RPRX Stock Holding History
Bought
Maintained
Sold
| Quarter | Market Value | Status | Shares |
Shares Change % | Capital Flow | Portfolio Weight | Portfolio Position | |
|---|---|---|---|---|---|---|---|---|
|
2025
Q2 | $108M | Sell |
3,008,837
-113,694
| -4% | -$4.1M | 0.02% | 644 |
|
|
2025
Q1 | $97.2M | Sell |
3,122,531
-9,097
| -0.3% | -$283K | 0.02% | 667 |
|
|
2024
Q4 | $79.9M | Buy |
3,131,628
+130,025
| +4% | +$3.32M | 0.01% | 796 |
|
|
2024
Q3 | $84.9M | Buy |
3,001,603
+1,103,341
| +58% | +$31.2M | 0.02% | 765 |
|
|
2024
Q2 | $50.1M | Buy |
1,898,262
+65,257
| +4% | +$1.72M | 0.01% | 1076 |
|
|
2024
Q1 | $55.7M | Buy |
1,833,005
+62,017
| +4% | +$1.88M | 0.01% | 964 |
|
|
2023
Q4 | $49.7M | Buy |
1,770,988
+122,084
| +7% | +$3.43M | 0.01% | 978 |
|
|
2023
Q3 | $44.8M | Buy |
1,648,904
+173,315
| +12% | +$4.7M | 0.01% | 953 |
|
|
2023
Q2 | $45.4M | Buy |
1,475,589
+68,052
| +5% | +$2.09M | 0.01% | 913 |
|
|
2023
Q1 | $50.7M | Buy |
1,407,537
+46,358
| +3% | +$1.67M | 0.02% | 819 |
|
|
2022
Q4 | $53.8M | Buy |
1,361,179
+83,896
| +7% | +$3.32M | 0.02% | 759 |
|
|
2022
Q3 | $51.3M | Buy |
1,277,283
+109,998
| +9% | +$4.42M | 0.02% | 741 |
|
|
2022
Q2 | $49.1M | Buy |
1,167,285
+92,864
| +9% | +$3.9M | 0.02% | 763 |
|
|
2022
Q1 | $41.9M | Buy |
1,074,421
+86,335
| +9% | +$3.36M | 0.01% | 993 |
|
|
2021
Q4 | $39.4M | Buy |
988,086
+41,987
| +4% | +$1.67M | 0.01% | 1076 |
|
|
2021
Q3 | $34.2M | Buy |
946,099
+680,274
| +256% | +$24.6M | 0.01% | 1124 |
|
|
2021
Q2 | $10.9M | Buy |
265,825
+20,688
| +8% | +$848K | ﹤0.01% | 1951 |
|
|
2021
Q1 | $10.7M | Buy |
245,137
+64,636
| +36% | +$2.82M | ﹤0.01% | 1923 |
|
|
2020
Q4 | $9.04M | Sell |
180,501
-34,354
| -16% | -$1.72M | ﹤0.01% | 1922 |
|
|
2020
Q3 | $9.04M | Buy |
214,855
+53,188
| +33% | +$2.24M | ﹤0.01% | 1761 |
|
|
2020
Q2 | $7.85M | Buy |
+161,667
| New | +$7.85M | ﹤0.01% | 1786 |
|